Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Seoyoung Catherine Kim, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Seoyoung Kim and Brendan Everett.
Connection Strength

0.879
  1. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 Sep 28.
    View in: PubMed
    Score: 0.247
  2. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
    View in: PubMed
    Score: 0.192
  3. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes Obes Metab. 2016 08; 18(8):755-65.
    View in: PubMed
    Score: 0.170
  4. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014 Dec; 51(6):1015-23.
    View in: PubMed
    Score: 0.152
  5. Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. Rheumatology (Oxford). 2021 08 02; 60(8):3789-3798.
    View in: PubMed
    Score: 0.061
  6. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
    View in: PubMed
    Score: 0.057
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.